Abstracts tagged "Hepatitis and rheumatoid arthritis (RA)"

Abstract Number: 472 • 2017 ACR/ARHP Annual Meeting
Viral Hepatitis Influences Patient Reported Outcomes Measures in Rheumatoid Arthritis
Suraj Timilsina¹, Harlan Sayles², Bryant R. England³, James R. O'Dell⁴, Ted R. Mikuls⁵ and Kaleb Michaud², ¹Division of Rheumatology & Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Viral hepatitis may complicate the treatment of RA since select DMARD have the potential to cause hepatotoxicity or reactivation of latent viral infections. Whether…
Abstract Number: 1521 • 2016 ACR/ARHP Annual Meeting
Disease Characteristics and Change of Arthritis Activity According to Treatment in Hepatitis B Surface Antigen Positive Rheumatoid Arthritis Patients
Yeonghee Eun¹, Hyemin Jeong¹, Eun-Jung Park², Ji Young Chai³, Hyungjin Kim¹, Jaejoon Lee¹, Eun-Mi Koh¹ and Hoon-Suk Cha⁴, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Medicine, Division of Rheumatology, Department of Medicine, Jeju National University Hospital, Jeju University School of Medicine, Jeju, South Korea, ³Departement of Internal Medicine, Bundang Jesaeng General Hospital, Seongnam, Korea, The Republic of, ⁴Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Rheumatoid arthritis (RA) treatment may differ according to hepatitis B state and consequently bring about different outcome of arthritis. Only a small number of…
Abstract Number: 2655 • 2016 ACR/ARHP Annual Meeting
Prevalence and Risk Factors of Reactivation of Resolved Hepatitis B Virus in Rheumatoid Arthritis Patients Treated with Biological Disease-Modifying Anti-Rheumatic Drugs
Toshiyuki Watanabe¹, Shinji Fukaya² and Kazumasa Akikawa², ¹3rd Department of Internal Medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan, ²3rd Department of Internal medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan
Background/Purpose: Reactivation of hepatitis B virus (HBV) is one of the most serious complications in rheumatoid arthritis (RA) patients treated with biological disease-modifying anti-rheumatic drugs…
Abstract Number: 432 • 2016 ACR/ARHP Annual Meeting
Monitoring Hepatitis B Screening Compliance in Patients with Rheumatoid Arthritis (RA) Receiving Anti-TNF Therapy
Vedashree Panthulu¹ and John Waterman², ¹Rheumatology, University of Connecticut Health Center, Farmington, CT, ²Rheumatology, Connecticut VA Healthcare System, Newington, CT
Background/Purpose: The risk of infection in patients with RA is higher than in comparable patients but still the vaccination rates in RA patients are low. …
Abstract Number: 1365 • 2013 ACR/ARHP Annual Meeting
Incidence Of Hepatitis B Virus Reactivation In Patients With Rheumatoid Arthritis During Treatment With Biologics
Jun Nakamura¹, Takao Nagashima¹, Katsuya Nagatani², Taku Yoshio³, Masahiro Iwamoto⁴ and Seiji Minota⁵, ¹Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan, ²Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan, ³Division of Rheumatology and Clinical Immunology, Jichi Medical University, School of Medicine, Shimotsuke-shi, Tochigi-ken, Japan, ⁴Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Tochigi, Japan, ⁵The Safety Evaluation Committee of Actemra® for JIA, Tokyo, Japan
Background/Purpose: Reactivation of hepatitis B virus (HBV) is very problematic in patients who are receiving biologics. Optimal precaution and management for those patients are still…
Abstract Number: 378 • 2013 ACR/ARHP Annual Meeting
HBV Reactivation and Consequent Hepatitis In Rheumatoid Arthritis Patients With Different HBV Carring State: A Clinical Observation Follow-Up
Lie Dai, An Qi Liang, Ying Qian Mo, Jian Da Ma, Le Feng Chen, Dong Hui Zheng and Lang Jing Zhu, Division of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
Background/Purpose: Approximate 7.2% Chinese were infected with hepatitis B virus (HBV), and the prevalence of concurrent HBV carriers in Chinese rheumatoid arthritis (RA) patients was…
Abstract Number: 175 • 2012 ACR/ARHP Annual Meeting
The Impact of Hepatitis Screening On Diagnosis and Treatment in Rheumatoid Arthritis
Richard Conway¹, Michele Doran², Finbar (Barry) D. O'Shea³ and Gaye Cunnane², ¹Rheumatology, St James's Hospital, Dublin, Ireland, ²Dept of Rheumatology, St James's Hospital, Dublin, Ireland, ³Rheumatology Dept, St James's Hospital, Dublin, Ireland
Background/Purpose: Hepatitis testing is an important pre-requisite to the diagnosis and treatment of patients with rheumatic disease. Joint symptoms may be a manifestation of acute…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].